Ensign Peak Advisors
REGN icon

Ensign Peak Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Ensign Peak Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Buy
19,052
+4,203
+28% +$3.22M 0.03% 344
2025
Q4 		$11.5M Sell
14,849
-16,314
-52% -$11.1M 0.02% 386
2025
Q3 		$17.5M Buy
31,163
+6,385
+26% +$3.61M 0.03% 336
2025
Q2 		$13M Sell
24,778
-18,898
-43% -$10.5M 0.02% 411
2025
Q1 		$27.7M Buy
43,676
+2,027
+5% +$1.39M 0.05% 255
2024
Q4 		$29.7M Sell
41,649
-1,093
-3% -$917K 0.05% 258
2024
Q3 		$44.9M Sell
42,742
-85,969
-67% -$95.7M 0.08% 201
2024
Q2 		$135M Sell
128,711
-4,471
-3% -$4.33M 0.25% 80
2024
Q1 		$128M Sell
133,182
-5,964
-4% -$5.67M 0.23% 88
2023
Q4 		$122M Buy
139,146
+11,490
+9% +$9.46M 0.24% 94
2023
Q3 		$105M Buy
127,656
+3,003
+2% +$2.36M 0.22% 96
2023
Q2 		$89.6M Buy
124,653
+76,094
+157% +$58.7M 0.18% 109
2023
Q1 		$39.9M Sell
48,559
-2,298
-5% -$1.73M 0.09% 198
2022
Q4 		$36.7M Buy
50,857
+228
+0.5% +$168K 0.08% 217
2022
Q3 		$34.9M Sell
50,629
-9,475
-16% -$5.96M 0.09% 201
2022
Q2 		$35.5M Buy
60,104
+14,405
+32% +$9.36M 0.08% 199
2022
Q1 		$31.9M Sell
45,699
-10,524
-19% -$6.66M 0.06% 228
2021
Q4 		$35.5M Sell
56,223
-33,665
-37% -$20.7M 0.07% 232
2021
Q3 		$54.4M Sell
89,888
-8,190
-8% -$5.08M 0.11% 165
2021
Q2 		$54.8M Sell
98,078
-4,258
-4% -$2.16M 0.11% 166
2021
Q1 		$48.4M Sell
102,336
-35,203
-26% -$17.1M 0.1% 170
2020
Q4 		$66.4M Sell
137,539
-13,692
-9% -$7.39M 0.15% 139
2020
Q3 		$84.7M Sell
151,231
-4,366
-3% -$2.65M 0.21% 93
2020
Q2 		$97M Buy
155,597
+70,382
+83% +$39.9M 0.26% 77
2020
Q1 		$41.6M Buy
85,215
+42,684
+100% +$17.6M 0.14% 119
2019
Q4 		$16M Buy
+42,531
New +$14.3M 0.04% 331

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ensign Peak Advisors's REGN Position: Q1 2026 in Review

Ensign Peak Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 28% in Q1 2026, buying an estimated $3.22M and bringing the position to 19,052 shares worth $14.7M. The position accounts for 0.03% of the portfolio, ranked #344.

Ensign Peak Advisors first reported a position in REGN in Q4 2019 and has held it in 26 quarters since. The position peaked at $135M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Ensign Peak Advisors held 19,052 shares of Regeneron Pharmaceuticals worth $14.7M as of Q1 2026.
  • Ensign Peak Advisors bought 4,203 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.22M.
  • Regeneron Pharmaceuticals made up 0.03% of Ensign Peak Advisors's portfolio in Q1 2026, its #344 holding.
  • Ensign Peak Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Regeneron Pharmaceuticals position peaked at $135M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.